论文部分内容阅读
采用3 2 P -GTMS治疗前列腺增生 ,能抑制前列腺间质细胞增生 ,改善排尿障碍症状。 (1)取 7条雄性健康草犬 ,以 2 5mg/kg丙睾每周 3次肌肉注射 ,持续 30d ,制成前列腺增生模型。 5条草犬模型在超声引导下注入 9.2 5— 74MBq/mL不等的3 2 P -GTMS ,分别于 30、6 0、90d活检 ,了解前列腺破坏、缩小数据。 2条草犬模型不予3 2 P -GTMS治疗 ,维持肌肉注射丙酸睾酮 ,直至治疗草犬疗效观察结束后作前列腺增生后缩小率比较。 (2 )根据草犬模型提供资料对 34例前列腺增生患者也行在超声引导下穿刺 ,注入3 2 P -GTMS 111± 18.5MBq ,分别于 30、6 0、90d测定前列腺容积 ,尿流率 ,残余尿及I -PSS评分结果 ,部分患者作活检病理。表明 7条草犬经注射丙酸睾酮后 30d ,前列腺平均增大 2倍以上。经3 2 P -GTMS治疗的 5条前列腺增生模型草犬的前列腺均出现前列腺细胞变性 ,炎性细胞浸润。当3 2 P -GTMS用量大于 13.88MBq/mL时呈显效结果 ,90d平均缩小率 >4 3.4 %,而对照组平均缩小率 <13%。 34例前列腺增生患者治疗 90d后前列腺缩小 17%,最大尿流率增加 4 1%,残余尿减少 74 %,I -PSS评分下降 31%,(P <0 .0 1)。病理切片结果显示 :增生前列腺细胞变性 ,萎缩。实验结果提示 ,采用B超引导下穿刺 ,在增生的前列腺内注入3 2 P
The use of 3 2 P -GTMS treatment of benign prostatic hyperplasia, can inhibit prostate stromal cell proliferation and improve symptoms of voiding disorders. (1) Seven male healthy dogs were injected intramuscularly with 25mg / kg of testosterone for 3 days per week for 30 days to make a model of benign prostatic hyperplasia. Five dogs were injected with 9.2 5-74 MBq / mL 3 2 P -GTMS under ultrasound guidance. The biopsies were taken at 30, 60, 90 days respectively to understand the damage of the prostate and reduce the data. The two models of dogs were not treated with 3 2 P -GTMS, and intramuscular injection of testosterone propionate was administered until the reduction in prostatic hyperplasia was observed after the curative effect was observed. (2) According to the model of cynomolgus, thirty-four patients with prostatic hyperplasia were also punctured by ultrasound guidance, and were injected with 111 ± 18.5MBq of 321 P -GTMS. Prostatic volume and uroflow rate were measured at 30, 60, Residual urine and I-PSS score results, some patients for biopsy. The results showed that seven dogs were injected with testosterone propionate 30d, the average prostate increased more than 2 times. Prostate degeneration and inflammatory cell infiltration were found in the prostate of 5 BPH model dogs treated with 3 2 P -GTMS. Significant results were obtained when the amount of 3 2 P -GTMS was greater than 13.88 MBq / mL, the average reduction rate of 90 days was> 3.4%, while the average reduction rate of control group was <13%. Prostatic hyperplasia was reduced by 17%, the maximal uroflow rate increased by 41%, the residual urine decreased by 74% and the I-PSS score decreased by 31% (P <0.01) after 34 days of treatment. Pathological results showed that: Prostate cell proliferation, atrophy. Experimental results suggest that the use of B-guided puncture in the prostatic hyperplasia into the 3 2 P